Turkey

Sisecam: Better than expected results on all fronts

  • Sisecam reported TL 5,379mn net income in 2Q22 which was 37% above our estimate and 35% above consensus estimate.

  • SISE'S EBITDA surged by 204% y/y to TL5,637mn, which was 8% higher than our estimate and 5% higher than consensus.

  • The company generated 24.2% EBITDA margin in 2Q22, 159bps higher than our estimate of 22.6%

https://cdn.tellimer.com/providers/badge-ata-invest-bZ2qBXVWtZfl26qH3OLjfMn9TkdTsjoY6bSn27iv.png
Mustafa Bayram @ ATA Invest
August 5th, 2022
This is a premium report that requires access to ATA Invest
ATA Invest ATA Invest

Coverage

Turkey

About

ATA Holding is a third-generation family-owned conglomerate, primarily active in financial services, food & retail, technology and rea estate. ATA Group consists of more than 20 companies, with a total consolidated sales figure exceeding US$2.0bn.

Services

Personal solutions
Add-on
This includes investment consultancy, asset management, pension services, and more.
Corporate solutions
Add-on
We offer comprehensive services relating to mergers and acquisitions and privatisation products
Full list of services

Recommendations

Access to recommendations is a Pro feature.

Most Read

1 ∙ Sovereign ∙ Kenya
Kenya: Restructuring concerns and fiscal slippage weigh on bonds
2 ∙ Macro ∙ Romania
Romania's new fiscal reforms hope to ensure seamless EU funding
3 ∙ Weekend Reading ∙ Global
Uranium's price surge sparks emerging market opportunities
4 ∙ Fixed Income Flash ∙ Sri Lanka
Sri Lanka: IMF review delayed by revenue shortfalls and financing assurances
5 ∙ Strategy Note ∙ Ukraine
Ukraine: Q2 growth print keeps GDP warrants on track

Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.

This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.